[Other] Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD)

Closed

oneenos Post time 2024-6-11 15:24:53 | Show all posts |Read mode

Reward20points

journal：Blood

Authors：Sameem Abedin; Mehdi Hamadani; Shernan G Holtan; Gary J. Schiller; Molly Gallogly; Edmund K. Waller; Satyajit Kosuri; Sunil H Abhyankar; Sarah M. Anand; Mahasweta Gooptu; Iming Cho; Simona Reed; Shih-Yao Lin; Jesse W Hall; Paul J Martin

Published date：2022-11-15

DOI：10.1182/blood-2022-163027

PDF link：https://ashpublications.org/bloo ... tients-with-Steroid

Article link：http://dx.doi.org/10.1182/blood-2022-163027

Article Source：American Society of Hematology。

Remark：

You can support us by donating, we would be very grateful.

Reply

Use magic Donate Report

All Reply0 Show all posts

Reply

oneenos Lv.3

Intermediate member

post
reply
points
390

[Other] Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD)

Reply

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Other] Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD) Copy

Reply

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Other] Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD)